Reviewing the somatic genetics of melanoma: from current to future analytical approaches
暂无分享,去创建一个
[1] D. Polsky,et al. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor , 2009, Proceedings of the National Academy of Sciences.
[2] R. Ward,et al. Dominantly inherited constitutional epigenetic silencing of MLH1 in a cancer-affected family is linked to a single nucleotide variant within the 5'UTR. , 2011, Cancer cell.
[3] J. Martínez,et al. Mutation and homozygous deletion analyses of genes that control the G1/S transition of the cell cycle in skin melanoma: p53, p21, p16 and p15 , 2005, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
[4] N. Hayward,et al. Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. , 2007, Cancer research.
[5] A. Børresen-Dale,et al. Identification of fusion genes in breast cancer by paired-end RNA-sequencing , 2011, Genome Biology.
[6] Tom Misteli,et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.
[7] M. Bulyk,et al. Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. , 1996, Cancer research.
[8] S. Gabriel,et al. High-throughput oncogene mutation profiling in human cancer , 2007, Nature Genetics.
[9] Thomas D. Wu,et al. Deep RNA sequencing analysis of readthrough gene fusions in human prostate adenocarcinoma and reference samples , 2011, BMC Medical Genomics.
[10] Syed Haider,et al. International Cancer Genome Consortium Data Portal—a one-stop shop for cancer genomics data , 2011, Database J. Biol. Databases Curation.
[11] Keith L. Ligon,et al. Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples , 2009, PloS one.
[12] J. Harbour. The genetics of uveal melanoma: an emerging framework for targeted therapy , 2012, Pigment cell & melanoma research.
[13] Mauro Biffoni,et al. The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. , 2008, Cancer research.
[14] Axel Hoos,et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.
[15] Gary D Bader,et al. International network of cancer genome projects , 2010, Nature.
[16] Nikhil Wagle,et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] S. Leung,et al. Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer , 2006, Nature Genetics.
[18] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[19] N. Hayward,et al. Characterization of the Melanoma miRNAome by Deep Sequencing , 2010, PloS one.
[20] N. Hayward,et al. Cutaneous melanoma susceptibility and progression genes. , 2005, Cancer letters.
[21] Huanming Yang,et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder , 2011, Nature Genetics.
[22] Lloyd J. Old,et al. Frequent MAGE Mutations in Human Melanoma , 2010, PloS one.
[23] Yue Xiong,et al. ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways , 1998, Cell.
[24] Myles G Cockburn,et al. Increasing burden of melanoma in the United States. , 2009, The Journal of investigative dermatology.
[25] M. Stratton,et al. Somatic mutations in human cancer: insights from resequencing the protein kinase gene family. , 2005, Cold Spring Harbor symposia on quantitative biology.
[26] A. Lupas,et al. The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain , 1995, Molecular and cellular biology.
[27] S. Nelson,et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.
[28] B. Druker,et al. RNAi screen for rapid therapeutic target identification in leukemia patients , 2009, Proceedings of the National Academy of Sciences.
[29] J. Schachter,et al. Mutagen-Specific Mutation Signature Determines Global microRNA Binding , 2011, PloS one.
[30] Jimmy Lin,et al. Delving into somatic variation in sporadic melanoma , 2012, Pigment cell & melanoma research.
[31] J. Tenenbaum,et al. A Melanoma Molecular Disease Model , 2011, PloS one.
[32] D. Pe’er,et al. An Integrated Approach to Uncover Drivers of Cancer , 2010, Cell.
[33] Michael A Choti,et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma , 2011, Nature Genetics.
[34] Elke Hacker,et al. Melanoma cell invasiveness is regulated by miR‐211 suppression of the BRN2 transcription factor , 2011, Pigment cell & melanoma research.
[35] T. Ishida,et al. TFG is a novel fusion partner of NOR1 in extraskeletal myxoid chondrosarcoma , 2004, Genes, chromosomes & cancer.
[36] Tijana Milenkovic,et al. Protein interaction network topology uncovers melanogenesis regulatory network components within functional genomics datasets , 2010, BMC Systems Biology.
[37] Ashish Choudhary,et al. High-throughput RNAi Screening Identifies a Role for TNK1 in Growth and Survival of Pancreatic Cancer Cells , 2011, Molecular Cancer Research.
[38] S. Davis,et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma , 2011, Nature Genetics.
[39] J. Arbiser,et al. Mitogen-actived protein kinase activation is an early event in melanoma progression. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[40] A. Ashworth,et al. Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines , 2011, BMC Medical Genomics.
[41] Lee T. Sam,et al. Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study , 2011, Science Translational Medicine.
[42] P. Meltzer,et al. Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma , 2009, Molecular Cancer Research.
[43] Gerald C. Chu,et al. Proinvasion metastasis drivers in early-stage melanoma are oncogenes. , 2011, Cancer cell.
[44] Alan Mackay,et al. Functional viability profiles of breast cancer. , 2011, Cancer discovery.
[45] J. Maguire,et al. Integrative analysis of the melanoma transcriptome. , 2010, Genome research.
[46] M. Herlyn,et al. Activated ras. Yet another player in melanoma? , 1996, The American journal of pathology.
[47] Jonathan Chernoff,et al. Faculty Opinions recommendation of COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. , 2011 .
[48] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[49] S. Steinberg,et al. Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.
[50] Damien Kee,et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. , 2010, Cancer cell.
[51] P. Hersey,et al. Cancer Therapy : Preclinical MEK-Independent Survival of B-RAFV 600 E Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX 4720 , 2011 .
[52] S. Sugano,et al. Large-scale identification and characterization of human genes that activate NF-κB and MAPK signaling pathways , 2003, Oncogene.
[53] A. Rosenwald,et al. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. , 1999, Blood.
[54] A. Benner,et al. Somatic mitochondrial mutations in melanoma resection specimens. , 2004, International journal of oncology.
[55] Zhengyan Kan,et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer , 2011, Nature Genetics.
[56] K. Dutton-Regester,et al. Identification of TFG (TRK‐fused gene) as a putative metastatic melanoma tumor suppressor gene , 2012, Genes, chromosomes & cancer.
[57] T. Golub,et al. Modeling genomic diversity and tumor dependency in malignant melanoma. , 2008, Cancer research.
[58] B. Garcia,et al. The histone variant macroH2A suppresses melanoma progression through regulation of CDK8 , 2010, Nature.
[59] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[60] Tom Royce,et al. A comprehensive catalogue of somatic mutations from a human cancer genome , 2010, Nature.
[61] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[62] C. V. Jongeneel,et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma , 2011, Nature Genetics.
[63] J. Bartek,et al. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. , 1996, Cancer research.
[64] P. Hersey,et al. MEK-Independent Survival of B-RAFV600E Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX4720 , 2010, Clinical Cancer Research.
[65] S. Ariyan,et al. Genome-wide screen of promoter methylation identifies novel markers in melanoma. , 2009, Genome research.
[66] D. Pinkel,et al. Somatic activation of KIT in distinct subtypes of melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] A. Balakrishnan,et al. Molecular profiling of the “plexinome” in melanoma and pancreatic cancer , 2009, Human mutation.
[68] Andrew D. Yates,et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer , 2005, Nature Genetics.
[69] J. Hansson,et al. Mutations of PIK3CA are rare in cutaneous melanoma , 2006, Melanoma research.
[70] Michael G. Roth,et al. Genome-Wide siRNA-Based Functional Genomics of Pigmentation Identifies Novel Genes and Pathways That Impact Melanogenesis in Human Cells , 2008, PLoS genetics.
[71] Francesca Demichelis,et al. Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. , 2011, Genome research.
[72] Kakajan Komurov,et al. Functional parsing of driver mutations in the colorectal cancer genome reveals numerous suppressors of anchorage-independent growth. , 2011, Cancer research.
[73] Tara L. Naylor,et al. microRNAs exhibit high frequency genomic alterations in human cancer. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[74] Steven J. M. Jones,et al. Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.
[75] M. Serrano,et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma , 1995, Science.
[76] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[77] W. Sellers,et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition , 2009, Proceedings of the National Academy of Sciences.
[78] D. Khaitan,et al. Epigenetic Regulation of MicroRNA Genes and the Role of miR-34b in Cell Invasion and Motility in Human Melanoma , 2011, PloS one.
[79] Francesca Demichelis,et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma , 2010, Nature Medicine.
[80] Jingwu Xie,et al. MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas , 2009, Cell cycle.
[81] J. Califano,et al. Nonsynonymous somatic mitochondrial mutations occur in the majority of cutaneous melanomas , 2008, Melanoma research.
[82] David I. K. Martin,et al. Inheritance of a cancer-associated MLH1 germ-line epimutation. , 2007, The New England journal of medicine.
[83] Ken Chen,et al. The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 , 1998, Cell.
[84] D. Valle,et al. DNA methylation regulates microRNA expression , 2007, Cancer biology & therapy.
[85] P. Guldberg,et al. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. , 1997, Cancer research.
[86] N. Hayward,et al. Cross-Platform Array Screening Identifies COL1A2, THBS1, TNFRSF10D and UCHL1 as Genes Frequently Silenced by Methylation in Melanoma , 2011, PloS one.
[87] R. Gibbs,et al. Frequent somatic MAP3K5 and MAP3K9 mutations in metastatic melanoma identified by exome sequencing , 2011, Nature Genetics.
[88] G. Mills,et al. A novel AKT3 mutation in melanoma tumours and cell lines , 2008, British Journal of Cancer.
[89] Lee T. Sam,et al. Transcriptome Sequencing to Detect Gene Fusions in Cancer , 2009, Nature.